Innovation | Ophthalmology Innovation Source

What Does the Leadership Shuffle Mean for Ophthalmology?

A Look at Recent Leadership Changes in Ophthalmology - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 073″] The combination of Pfizer and Allergan certainly creates some waves in ophthalmology. But did these choppy waters have anything to do with recent leadership changes in the sector? Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is Tom Salemi, your host. Thanks a lot for joining…

Inotek’s Southwell & McVicar Have Designs on Treating Glaucoma

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 070″] Inotek CEO David Southwell and William K. McVicar PhD Executive Vice President, Chief Scientific Officer, share Inotek’s plan to bring to market a new first-line for glaucoma sufferers. Podcast Guest David P. Southwell Mr. Southwell has been President and CEO since August 2014, and led Inotek through its IPO and…

Emptying the OIS Reporter’s Notebook After OIS@AAO

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 069″] OIS Correspondents Michelle Dalton and Richard Kirkner pool their insights on the most compelling sights and insights of OIS, Subspecialty Day and AAO. The two scribes opine on exiting new disease targets, advances in drug delivery, the penetration of digital technology and why the `Pfizergan’ deal makes sense for ophthalmology.…

Taking in the View of 2015 & Beyond

This year’s Ophthalmology Innovation Summits are behind us. We’re piling content onto OIS.NET including the 2015 Year in Review by OIS Founder and Co-Chair Emmett Cunningham, MD. And, believe it or not, we’re eagerly accepting registration for our next OIS@ASCRS, which will be held on May 5 at the InterContinental New Orleans. (We are now…

Where Will `Pfizergan’ Fit in Ophthalmology

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 068″] Allergan has been a pillar of the ophthalmology sector for decades so its merger with Pfizer is a cause of concern for some. But ophthalmology leaders also see reason for optimism from the combination. The deal could bring greater firepower to ophthalmology R&D and M&A and some hope it’s a…

MicroOptx Pursues New MIGS Approach

Chris Pulling, CEO of MicroOptx, tells OISTV about its Brown Glaucoma Implant (new name pending). The implant is used to lower IOP by draining aqueous fluid. Unlike other implants, which divert fluid to other chambers of the eye, MicroOptx is shunts the fluid to the tear film. Speaking With: Chris Pulling Chris was most recently…

Oculeve’s Ackermann Talks Allergan

Michael Ackermann, CEO of start-up Oculeve, gives an update on his work with Allergan following the purchase of his company and its Dry Eye device. Ackermann explains how he’s fitting into Allergan’s folds and when we might expect to see Oculeve’s neurostimulation device. Speaking With: Michael Ackermann, PhD Michael is currently Vice President, Neurostimulation for…

Duker Sees “Energy” Being Added to Gene Therapy Field

Jay Duker, MD, Director of the New England Eye Center and Chairman of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, tells OISTV the approval of gene therapy products including Spark Therapeutics’ SPK-RPE65 would help the sector clear a “real and psychological” hurdle facing gene therapy companies. Speaking With: Jay Duker,…

OIS Innovation Award Presentation

This video honors Tom Frinzi and Dan Durrie, MD, for their successful leadership at WaveTec. Recipients: Tom Frinzi Thomas Frinzi is Senior Vice President of Abbott’s vision business, which includes a broad ophthalmology portfolio across the areas of cataracts, refractive surgery (LASIK) and eye health products. Prior to joining Abbott, Mr. Frinzi held a number…

Protecting & Monetizing IP – A Primer for Early Stage Entrepreneurs

Moderator: Casey McGlynn J. Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich & Rosati in 1990. It is a nationally recognized practice representing startups and emerging growth companies in the life sciences field–Medical Devices, Digital Health, Diagnostics and Biotechnology. View Full Profile Panelists: Mark S. Blumenkranz, MD Mark S. Blumenkranz, MD, MMS,…

Welcome & Chairman’s 2015 Year in Review

Presenter: Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals. View Full Profile

MDbackline

MDbackline has developed a cloud-based, secure, online software that automates physician contact with patients outside of the office and can work with any electronic health records (EHR) system, founder John Hovanesian, MD, reported at OIS@AAO 2015. The system allows patients to submit questions to doctors electronically via tablet, phone or computer, allows doctors to provide…